{"id":767,"date":"2026-05-07T07:14:19","date_gmt":"2026-05-07T07:14:19","guid":{"rendered":"https:\/\/genes2me.com\/blog\/?p=767"},"modified":"2026-05-07T07:14:20","modified_gmt":"2026-05-07T07:14:20","slug":"catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection","status":"publish","type":"post","link":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/","title":{"rendered":"Catching Cancer Early: Liquid Biopsy and NGS at the Frontline of Detection"},"content":{"rendered":"\n
\"\"
Liquid Biopsy – NGS Assays<\/figcaption><\/figure>\n\n\n\n

In oncology, timing is everything. Even with treatment improvements, many cancers are still being diagnosed too late for effective action. Early cancer diagnosis is a patient’s strongest weapon against cancer. Liquid biopsy<\/a> transforms cancer diagnoses and strengthening targeted therapies towards the highest likelihood of clinical success. Advanced cellular and molecular methodologies stand at the frontline of this innovation. High-throughput Next Generation Sequencing (NGS) technologies powers liquid biopsy analysis by profiling cell-free DNA (cfDNA). Circulating tumour DNA (ctDNA), the tumour-derived fraction of cfDNA provides the most meaningful insights.\u00a0<\/p>\n\n\n\n

What if a simple blood test could pick up on cancer\u2019s earliest molecular signals before the disease becomes apparent?<\/strong><\/h4>\n\n\n\n

As next-generation sequencing<\/a> (NGS) intersects with the study of circulating DNA, a significant shift in cancer biology is underway. At this crucial juncture, liquid biopsy is changing how we understand, detect and monitor cancer through sensitive, non-invasive genomic insights.<\/p>\n\n\n\n

Looking back, why do traditional screenings fall short in early cancer detection?<\/strong><\/h4>\n\n\n\n
\"\"
G2M Liquid Biopsy Assays<\/figcaption><\/figure>\n\n\n\n

Cancer remains a leading cause of death globally, and survival rates depend largely on how early the disease is detected. Cancer remains a leading cause of death globally, and early detection largely determines patient survival.\u00a0<\/p>\n\n\n\n

While screening tools such as Pap smears and mammograms have improved early diagnosis for some cancers, they have limitations. Many cancers still lack reliable screening methods. Existing screening approaches often deliver low sensitivity, cause patient discomfort, and fail to address diverse tumour types.\u00a0<\/p>\n\n\n\n

Clinicians often catch cancer only after symptoms appear, usually at later stages when treatment choices are fewer and outcomes are poorer. \u00a0<\/p>\n\n\n\n

Traditional tissue biopsies are an essential diagnostic tool in oncology, their invasive nature and procedural demands can limit their suitability. Additionally, a single tissue sample may not capture tumour diversity and isn\u2019t practical for long-term monitoring.<\/p>\n\n\n\n

These limitations expose a critical gaps in early detection and disease tracking. They delay timely intervention and restrict continuous monitoring. To overcome these challenges, clinicians increasingly seek less invasive, more scalable diagnostic solutions. <\/p>\n\n\n\n

Liquid Biopsy: Unlocking Early, Non\u2011Invasive Cancer Detection<\/a><\/strong><\/h4>\n\n\n\n

NGS-based liquid biopsies provide a strong yet straightforward alternative to traditional diagnostics, allowing for non-invasive tumour profiling. Liquid biopsies uncover tumour-derived biomarkers in body fluids particularly circulating tumour DNA (ctDNA). This aids in early diagnosis, treatment monitoring, and post-therapy follow-up.<\/p>\n\n\n\n

Among circulating substances such as circulating tumour cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles, cfDNA stands out as the most studied and useful biomarker. ctDNA (circulating tumour DNA) is a small part of total cell-free DNA released into the bloodstream during tumour cell death, with levels often linked to tumour burden and stage. Thanks to advancements in NGS sensitivity, ctDNA can now be detected at very low levels, enabling early mutation detection, monitoring of minimal residual disease, and insight into cancer long before it shows clinical signs.<\/p>\n\n\n\n

This capability positions liquid biopsy as a vital tool at the forefront of precision oncology.<\/p>\n\n\n\n

\"\"
NGS Assays<\/figcaption><\/figure>\n\n\n\n

From Innovation to Impact: Liquid Biopsy in Real\u2011World Oncology<\/strong><\/h4>\n\n\n\n

Translating these advances from the lab to the clinic requires assays that are not only sensitive, but also robust, scalable, and suited for real\u2011world samples\u2014 Genes2Me<\/a>‘s Liquid Biopsy NGS panels bring this promise into clinical practice.<\/p>\n\n\n\n

The G2M Liquid Biopsy Assay provides targeted, high-performance NGS panels for lung, breast, and colorectal cancers. It is designed for reliable detection from very low amounts of cfDNA (10\u201320 ng). With ultra-deep sequencing strategies and assay design, it enables sensitive and reproducible detection of clinically important variants, even at very low allele frequencies.<\/p>\n\n\n\n

Genes2Me is accelerating the transition of liquid biopsy\u2013powered NGS<\/a> from an emerging innovation to a much-needed tool for early, personalised cancer care.<\/p>\n","protected":false},"excerpt":{"rendered":"

In oncology, timing is everything. Even with treatment improvements, many cancers are still being diagnosed too late for effective action. Early cancer diagnosis is a…<\/p>\n","protected":false},"author":1,"featured_media":774,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"yoast_head":"\nLiquid Biopsy Solution | NGS | NIPT Diagnostic Kit | DNA Analysis<\/title>\n<meta name=\"description\" content=\"Solutions like Genes2Me liquid biopsy panels, next-generation sequencing assay, non-invasive analysis of circulating tumour DNA (ctDNA) - G2M\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liquid Biopsy Solution | NGS | NIPT Diagnostic Kit | DNA Analysis\" \/>\n<meta property=\"og:description\" content=\"Solutions like Genes2Me liquid biopsy panels, next-generation sequencing assay, non-invasive analysis of circulating tumour DNA (ctDNA) - G2M\" \/>\n<meta property=\"og:url\" content=\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/\" \/>\n<meta property=\"og:site_name\" content=\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T07:14:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-07T07:14:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/05\/Liquid-Biopsy-and-NGS-Blog-3.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"525\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Genes2Me\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Genes2Me\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"contentUrl\":\"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg\",\"width\":150,\"height\":69,\"caption\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\"},\"image\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/genes2me.com\/blog\/#website\",\"url\":\"https:\/\/genes2me.com\/blog\/\",\"name\":\"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems\",\"description\":\"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome\",\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/genes2me.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/\",\"url\":\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/\",\"name\":\"Liquid Biopsy Solution | NGS | NIPT Diagnostic Kit | DNA Analysis\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#website\"},\"datePublished\":\"2026-05-07T07:14:19+00:00\",\"dateModified\":\"2026-05-07T07:14:20+00:00\",\"description\":\"Solutions like Genes2Me liquid biopsy panels, next-generation sequencing assay, non-invasive analysis of circulating tumour DNA (ctDNA) - G2M\",\"breadcrumb\":{\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/genes2me.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catching Cancer Early: Liquid Biopsy and NGS at the Frontline of Detection\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/\"},\"author\":{\"name\":\"Genes2Me\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\"},\"headline\":\"Catching Cancer Early: Liquid Biopsy and NGS at the Frontline of Detection\",\"datePublished\":\"2026-05-07T07:14:19+00:00\",\"dateModified\":\"2026-05-07T07:14:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/\"},\"wordCount\":627,\"publisher\":{\"@id\":\"https:\/\/genes2me.com\/blog\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa\",\"name\":\"Genes2Me\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g\",\"caption\":\"Genes2Me\"},\"description\":\"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.\",\"sameAs\":[\"https:\/\/www.genes2me.com\/\"],\"url\":\"https:\/\/genes2me.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liquid Biopsy Solution | NGS | NIPT Diagnostic Kit | DNA Analysis","description":"Solutions like Genes2Me liquid biopsy panels, next-generation sequencing assay, non-invasive analysis of circulating tumour DNA (ctDNA) - G2M","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/","og_locale":"en_US","og_type":"article","og_title":"Liquid Biopsy Solution | NGS | NIPT Diagnostic Kit | DNA Analysis","og_description":"Solutions like Genes2Me liquid biopsy panels, next-generation sequencing assay, non-invasive analysis of circulating tumour DNA (ctDNA) - G2M","og_url":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/","og_site_name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","article_published_time":"2026-05-07T07:14:19+00:00","article_modified_time":"2026-05-07T07:14:20+00:00","og_image":[{"width":700,"height":525,"url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2026\/05\/Liquid-Biopsy-and-NGS-Blog-3.jpeg","type":"image\/jpeg"}],"author":"Genes2Me","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Genes2Me","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/genes2me.com\/blog\/#organization","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","url":"https:\/\/genes2me.com\/blog\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","contentUrl":"https:\/\/genes2me.com\/blog\/wp-content\/uploads\/2023\/09\/cropped-G2M150x150.jpg","width":150,"height":69,"caption":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems"},"image":{"@id":"https:\/\/genes2me.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"WebSite","@id":"https:\/\/genes2me.com\/blog\/#website","url":"https:\/\/genes2me.com\/blog\/","name":"Genes2Me Blog - CE IVD Approved RT-PCR POC, NGS Testing Kits Solutions Instruments Device Systems","description":"Real Time PCR Molecular Diagnostics NGS Cancer Screening Sequencing COVID-19 Rapid Antigen Antibody Made in India Manufacturer Clinical\/Whole Exome","publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/genes2me.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/","url":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/","name":"Liquid Biopsy Solution | NGS | NIPT Diagnostic Kit | DNA Analysis","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/#website"},"datePublished":"2026-05-07T07:14:19+00:00","dateModified":"2026-05-07T07:14:20+00:00","description":"Solutions like Genes2Me liquid biopsy panels, next-generation sequencing assay, non-invasive analysis of circulating tumour DNA (ctDNA) - G2M","breadcrumb":{"@id":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/genes2me.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Catching Cancer Early: Liquid Biopsy and NGS at the Frontline of Detection"}]},{"@type":"Article","@id":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/#article","isPartOf":{"@id":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/"},"author":{"name":"Genes2Me","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa"},"headline":"Catching Cancer Early: Liquid Biopsy and NGS at the Frontline of Detection","datePublished":"2026-05-07T07:14:19+00:00","dateModified":"2026-05-07T07:14:20+00:00","mainEntityOfPage":{"@id":"https:\/\/genes2me.com\/blog\/2026\/05\/07\/catching-cancer-early-liquid-biopsy-and-ngs-at-the-frontline-of-detection\/"},"wordCount":627,"publisher":{"@id":"https:\/\/genes2me.com\/blog\/#organization"},"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/10206ca125f3a19893d76130599c48aa","name":"Genes2Me","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/genes2me.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d657e6ab646ef1896bc855e2b96e924e?s=96&d=mm&r=g","caption":"Genes2Me"},"description":"Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry\u2019s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics\u2014delivering integrated solutions that advance precision medicine and improve lives worldwide.","sameAs":["https:\/\/www.genes2me.com\/"],"url":"https:\/\/genes2me.com\/blog\/author\/admin\/"}]}},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/767"}],"collection":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/comments?post=767"}],"version-history":[{"count":1,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/767\/revisions"}],"predecessor-version":[{"id":777,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/posts\/767\/revisions\/777"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media\/774"}],"wp:attachment":[{"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/media?parent=767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/categories?post=767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/genes2me.com\/blog\/wp-json\/wp\/v2\/tags?post=767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}